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thies (IIMs) that may be related to statins. 
All forms of IIMs are considered rare dis‑
eases. In USA, DM has prevalence of ~1‑6 
patients per 100,000 persons, while PM has 
a prevalence ~10 per 100,000 [2].
In this context, some cases of association 
of statins with polymyositis [3‑16] and with 
dermatomyositis [10‑12,15,17‑35] have 
been described.
A rate of exposure to statins up to 48% 
was found among patients with PM or DM 
over 50 years of age [10].
The outdated, but still used, diagnostic cri‑
teria for PM and DM, according to Bohan 
and Peter [36,37], are:
 y Increase in muscle enzymes;
 y Weakness of proximal muscles;
IntroduCtIon
Statins
Due to the wide diffusion of statins, which 
have the undoubted merit of increasing the 
survival rate in patients affected by cardio‑
vascular disease, particular attention should 
be paid to their side effects. The most com‑
mon ones are toxic myopathies, affecting 
2‑20% of patients [1], that generally re‑
solve after drug discontinuation. The risk of 
statin myopathy and creatine phosphokinase 
(CPK) increase is dose‑dependent.
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Abstract
BACKGROUND: Statins are a well‑recognized cause of a variety of skeletal myopathic effects, 
which generally resolve when discontinuing the treatment. Among autoimmune manifestations 
associated with statins, there are typical polymyositis (PM) and typical dermatomyositis (DM).
OBJECTIVE: To perform a review on published case reports and case series about 
statin‑associated PM and DM.
METHODS: This literature comprehensive search was conducted mainly on PubMed, but also 
congress abstracts and university websites were considered. Given the paucity of cases, the search 
was extended to include articles in all languages with English abstract.
RESULTS: Twenty‑eight PM and 30 DM cases have been described with prevalence in female 
(64%) and senile age. The drugs most frequently involved were atorvastatin and simvastatin. 
The differential diagnosis should be made among the main myositis subtypes: immuno‑mediated 
necrotizing myopathy (IMNM), inclusion body myositis (IBM), and overlap syndrome with 
myositis (OM), including anti‑synthetase syndrome (ASS).
CONCLUSIONS: Even though the onset of polymyositis or dermatomyositis is a rare 
phenomenon, it is advisable to consider their presence in patients taking statins and with a 
non‑reversible elevation of creatine phosphokinase. 
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 y Electromyographic alterations;
 y Bioptic alterations; and
 y Characteristic skin rash.
As described in Table I, PM and DM are 
judged “definite”, “probable”, or “possible” 
according to the number of criteria met by 
the patient.
The classification of inflammatory my‑
opathies has undergone several revisions 
[38‑40] since the earliest descriptions by 
Bohan and Peter. 
Five main subtypes of myositis, i.e. der‑
matomyositis (DM and juvenile DM), nec‑
rotizing myopathy (NM), PM, overlap 
myositis (OM and anti‑synthetase syn‑
drome—ASS), and inclusion body myositis 
(IBM), have been well described in a recent 
German review [41] (Table II).
In September 2018, Selva‑O’Callaghan 
and colleagues published on Lancet Neu‑
rology a new classification of inflamma‑
tory myopathies in the adult [42] based 
on the clinical characteristics of the main 
clinical and phenotype‑specific autoanti‑
body groups, in which they specified also 
that the diagnosis of PM is a diagnosis of 
exclusion.
In the same period a further classifica‑
tion was published also based on a targeted 
clinical‑serological approach [43]. In ref‑
erence to the 708 variables (in particular 
myositis‑specific autoantibodies—MSA) 
collected in 260 adult patients of the French 
register on myositis, 4 clusters of patients 
emerged (IBM, IMNM, DM, ASS), while 
PM did not more found place.
Besides clinical criteria, magnetic reso‑
nance imaging (MRI) [39,44] can be use‑
Polymyositis dermatomyositis
Definite 4 criteria 3 criteria
Probable 3 criteria 2 criteria
Possible 2 criteria 1 criterion
table I. Criteria for the 
diagnosis of polymyositis 
and dermatomyositis. 
Modified from [36,37]
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Long finger flexors, knee 
extensors, dysphagia
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PL‑12, HA, EJ, KS, 
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on sarcolemma
Endomysial CD8+ T cells, MHC 
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response except for 
malignancy or ILD
No basic immunosuppression; 
Probatory IVIG in selected 
patients justifiable;
Severe dysphagia: local 
botulinum toxin or myotomy, 
percutaneous feeding tube.
Usually refractory to 
treatment
table II. Overview of the clinical presentation, auto‑antibodies, muscle pathology and treatment in the 
main subtypes of myositis. Modified from [41].
Ab = antibody; ASS = anti‑synthetase syndrome; AZA = azathioprine; CD8+ T cells = cluster of differentiation 8 
of cytotoxic T cells; cN1A = anti‑cytosilic 5'‑nucleotidase 1A Ab; COX = cytochrome oxidase staining in muscle 
fibers; CPK = creatine phosphokinase; CsA = cyclosporine A; CYC = cyclophosphamide; DM = dermatomyositis; 
EJ = anti‑glycyl tRNA synthetase Ab; GS = glucocorticoids; HA = anti‑tyrosyl tRNA syntethase Ab; 
HMGCR = anti‑3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase autoantibodies; IBM = inclusion body myositis; 
ILD = interstitial lung disease; IVIG = intravenous immunoglobulin G; JDM = juvenile dermatomyositis; Jo‑1 = anti‑histidil 
tRNA synthetase Ab; KS = anti‑asparaginyl tRNA synthetase Ab; Ku = antibodies against Ku antigen (p70 and p80 
subunits); MDA5 = anti‑melanoma differentiation‑associated gene 5 Ab; MHC = major histocompatibility complex; 
Mi‑2 = anti‑chromodomain helicase DNA binding protein 4 Ab; MMF = mycophenolate mofetil; MTX = methotrexate; 
NM = necrotizing myopathy; NXP2 = anti‑nuclear matrix protein 2 Ab; OJ = anti‑ isoleucyl tRNA synthetase 
Ab; OM = overlap myositis; PL‑7 = anti‑threonyl tRNA synthetase Ab; PL‑12 = anti‑alanyl tRNA synthetase 
Ab; PM/ Scl = anti‑PM‑Scl‑75 and PM/Scl‑100 polypeptides Ab; Ro/SS‑A = anti‑Sjögren’s‑syndrome‑related 
antigen A (against the Ro52 and Ro60 autoantigen) Ab; RTX = rituximab; SAE = anti‑small ubiquitin‑like modifier 
activating enzyme Ab; SLE = systemic lupus erythematosus; SRP = anti‑signal recognition particle autoantibodies; 
SS‑B = anti‑Sjögren’s‑syndrome‑related La antigen Ab; TIF‑1γ = anti‑transcription intermediary factor gamma 
Ab; U‑snRNP = anti‑U1 small nuclear ribonucleoprotein particle Ab; Zo = anti‑phenylalanyl synthetase Ab
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drome—ASS), and inclusion body myositis 
(IBM), have been well described in a recent 
German review [41] (Table II).
In September 2018, Selva‑O’Callaghan 
and colleagues published on Lancet Neu‑
rology a new classification of inflamma‑
tory myopathies in the adult [42] based 
on the clinical characteristics of the main 
clinical and phenotype‑specific autoanti‑
body groups, in which they specified also 
that the diagnosis of PM is a diagnosis of 
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clinical‑serological approach [43]. In ref‑
erence to the 708 variables (in particular 
myositis‑specific autoantibodies—MSA) 
collected in 260 adult patients of the French 
register on myositis, 4 clusters of patients 
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nance imaging (MRI) [39,44] can be use‑
Polymyositis dermatomyositis
Definite 4 criteria 3 criteria
Probable 3 criteria 2 criteria
Possible 2 criteria 1 criterion
table I. Criteria for the 
diagnosis of polymyositis 
and dermatomyositis. 
Modified from [36,37]




onset; short, benign 










































Long finger flexors, knee 
extensors, dysphagia
CPK level Normal or around 10 
‑50 fold elevated




Around 10‑50 fold 
elevated
Normal to 15 fold elevated






Unspecific ASS: Jo‑1, PL‑7, 
PL‑12, HA, EJ, KS, 
Zo, OJ
Other OM: Ku, Ro/








atrophy, MHC class 












necrosis, MHC class 
I and II, complement 
on sarcolemma
Endomysial CD8+ T cells, MHC 
class I, amyloid, vacuoles, 
tubulofilaments, mitochondrial 































response except for 
malignancy or ILD
No basic immunosuppression; 
Probatory IVIG in selected 
patients justifiable;
Severe dysphagia: local 
botulinum toxin or myotomy, 
percutaneous feeding tube.
Usually refractory to 
treatment
table II. Overview of the clinical presentation, auto‑antibodies, muscle pathology and treatment in the 
main subtypes of myositis. Modified from [41].
Ab = antibody; ASS = anti‑synthetase syndrome; AZA = azathioprine; CD8+ T cells = cluster of differentiation 8 
of cytotoxic T cells; cN1A = anti‑cytosilic 5'‑nucleotidase 1A Ab; COX = cytochrome oxidase staining in muscle 
fibers; CPK = creatine phosphokinase; CsA = cyclosporine A; CYC = cyclophosphamide; DM = dermatomyositis; 
EJ = anti‑glycyl tRNA synthetase Ab; GS = glucocorticoids; HA = anti‑tyrosyl tRNA syntethase Ab; 
HMGCR = anti‑3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase autoantibodies; IBM = inclusion body myositis; 
ILD = interstitial lung disease; IVIG = intravenous immunoglobulin G; JDM = juvenile dermatomyositis; Jo‑1 = anti‑histidil 
tRNA synthetase Ab; KS = anti‑asparaginyl tRNA synthetase Ab; Ku = antibodies against Ku antigen (p70 and p80 
subunits); MDA5 = anti‑melanoma differentiation‑associated gene 5 Ab; MHC = major histocompatibility complex; 
Mi‑2 = anti‑chromodomain helicase DNA binding protein 4 Ab; MMF = mycophenolate mofetil; MTX = methotrexate; 
NM = necrotizing myopathy; NXP2 = anti‑nuclear matrix protein 2 Ab; OJ = anti‑ isoleucyl tRNA synthetase 
Ab; OM = overlap myositis; PL‑7 = anti‑threonyl tRNA synthetase Ab; PL‑12 = anti‑alanyl tRNA synthetase 
Ab; PM/ Scl = anti‑PM‑Scl‑75 and PM/Scl‑100 polypeptides Ab; Ro/SS‑A = anti‑Sjögren’s‑syndrome‑related 
antigen A (against the Ro52 and Ro60 autoantigen) Ab; RTX = rituximab; SAE = anti‑small ubiquitin‑like modifier 
activating enzyme Ab; SLE = systemic lupus erythematosus; SRP = anti‑signal recognition particle autoantibodies; 
SS‑B = anti‑Sjögren’s‑syndrome‑related La antigen Ab; TIF‑1γ = anti‑transcription intermediary factor gamma 
Ab; U‑snRNP = anti‑U1 small nuclear ribonucleoprotein particle Ab; Zo = anti‑phenylalanyl synthetase Ab
ful to make the right diagnosis. MRI with 
whole‑body technique (WBMRI) is consid‑
ered particularly useful for identifying the 
involvement of muscles: parameters such 
as inflammation, fibrosis, and atrophy can 
be used to determine the pattern of disease 
activity even at subclinical level [45‑49]. In 
addition, MRI guides the choice of the site 
for muscle biopsy.
Figure 1, coming from a personal case 
report [50], highlights the typical MRI el‑
ements, which are suggestive for DM/PM.
IIMs can be treated with glucocorticoids 
(initial and basic treatment) and with immu‑
nosuppressants (methotrexate, azathioprine, 
mycophenolate mofetil). An additional or 
alternative therapy may be undertaken with 
cyclosporin A (or tacrolimus) or intravenous 
immunoglobulin, with therapy escalation to 
rituximab or cyclophosphamide.
Treatment with repository corticotropin 
injection (RCI) in a recent open label clini‑
cal trial [51] was effective, safe and toler‑
able, and led to a steroid dose reduction in 
adult patients with myositis refractory to 
glucocorticoid and traditional immunosup‑
pressive drugs.
In this article, the possible implications 
of statins in autoimmunity have been thor‑
oughly considered with the support of a 
literature search.
LIterAture SeArCh StrAtegy
In this review, the literature search was 
conducted mainly on PubMed, but also 
congress abstracts and universities websites 
Figure 1. Example 
of thighs magnetic 
resonance imaging 





images show increased 
signal intensity. Intense 
edema of the muscular 
bundles of both 
quadriceps, especially 
on the left, of the large 
adductor muscle on 
the left, of the gracilis 
(blue arrow), and of the 
semitendinosus muscles. 
Subcutaneous edema 
between muscles and 
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were considered. The search terms used were: 
“myositis”, “myopathy”, “statins”, “muscular 
manifestations”, “dermatomyositis”, “poly‑
myositis”, “statin‑induced autoimmune 
myopathy”, “creatine (phospho) kinase”, 
“myoglobin”, and “troponin”. The keywords 
were combined with the Boolean operators 
“AND” and “OR”. Given the paucity of 
cases, we extended the search to include ar‑
ticles in all languages with English abstract. 
The selection of the descriptors was carried 
out in November 2018. No time limit was 
set in the search.
reSuLtS
Tables III and IV describe the main char‑
acteristics of case reports, related to the expo‑
sure to statins in 28 adult patients with poly‑
myositis [3‑10,12‑14,16] and in 30 adult pa‑



























































































42, M S 20 4 m 503 n.r. ‑ n.p. Myogenic 
and 
neurogenic




































56, F S n.r. 2 m 925 1:5120 ‑ n.p. Normal n.r. n.r. Endomysial T 
cell infiltration, 
type II muscle 
atrophy
Pr
54, F A n.r. 4 m 7400 ‑ ‑ n.p. Normal n.r. n.r. T cell infiltration, 
type II muscle 
atrophy
Pr
78, F F n.r. 4 m 1417 1:2150 +
(ASS)
n.p. Normal n.r. n.r. T cell infiltration, 
type II muscle 
atrophy
Pr





Wu Y, 2014 
[5], Canada
57, M n.r. 
unknown
u.k. 3831 n.r. n.r. n.p. Irritable 
myopathy






56, F A 10 Few y 946 n.r. n.r. n.p. Irritable 
myopathy
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77, F A 40‑80 25 y 704 n.r. n.r. n.p. Irritable 
myopathy






58, F A n.r. 60 m 7000 n.r. n.r. n.p. Irritable 
myopathy






59, F A 10 54 m 8200 n.r. n.r. n.p. Irritable 
myopathy






75, F n.r. 
unknown
u.k. 3741 n.r. n.r. n.p. Irritable 
myopathy






71, F R n.r. 19 m 974 n.r. n.r. n.p. Irritable 
myopathy






55, M A n.r. 1 m 1187 n.r. n.r. n.p. Irritable 
myopathy






47, F R 10 44 m 1656 n.r. n.r. n.p. Irritable 
myopathy









80, F P/F n.r. 14 m 355 ‑ n.r. n.p. Normal n.p. n.r. n.p. Po





60, F P/A/S 
n.r.
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n.p. n.r. Inflammatory 
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days























71, F A 20 5 y >4000 1:160 fine 
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55, M C 0.3 mg
A 10
2 w 14,611 
(aldolase 
355#)












































with attempt to 
break into the 
sarcoplasm
D
table III. Statin‑associated polymyositis (28 case reports). Most Authors used the diagnostic criteria 
according to Bohan and Peter [36,37].
* subacute;
^ +gemfibrozil
§ ethnicity: African American
# normal values: 1‑7 IU/l
‑ = negative; + = positive; A = atorvastatin; ANA = Anti‑nuclear antibody; 
anti‑HMGCR = 3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase autoantibodies ; anti‑Jo‑1 = aminoacyl‑tRNA 
histidyl synthetase autoantibodies; ASS = anti‑synthetase syndrome; anti‑SRP = anti‑signal recognition particle 
autoantibodies; C = cerivastatin; CPK = creatine phosphokinase; D = definite; EMG = electromyography; 
F = fluvastatin; HLA‑1 = human leukocyte antigen‑1; m = months; MHC = major histocompatibility 
complex; MRI = magnetic resonance imaging; n.p. = not performed; n.r. = not reported; P = pravastatin; 
Po = possible; Pr = probable; R = rosuvastatin; S = simvastatin; u.k. = unknown; y = years; w = weeks
> Table continued
95© 2018 The Authors. Published by SEEd srl. This is an open access article under  
the CC BY-NC 4.0 license (https://creativecommons.org/licenses/by-nc/4.0)



























































































66, F P 10 5 m >4000 n.r.
n.r.
n.r. n.p. Myopathic 
changes






50, M S n.r. 6 m 1045 1:250
n.r.








76, F S 10 18 m 1246 1:2560
n.r.









63, F L 20 24 m Increased n.r.
n.r.











44, M A 10 12 m >2000 1:2560
nucleolar































69, F P n.r. 24 m 6246 ‑ n.p. n.p. Normal n.r. n.r. Normal D
Thual, 2005 
[26], France














72, F A n.r. 48 m 4200 1:2400
n.r.







74, F S n.r. >36 m n.p. 1:1280
n.r.





74, F P n.r. 3 m 4400 n.p.
n.p.







84, F P n.r. 32 m 712 1:5000
n.r.
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85, F S n.r. 72 m 239 1:5000
n.r.







79, F A n.r. 60 m 1869 n.p.
n.p.




































50, M S n.r. 12 m 714 1:1600
n.r.















47, F A 5 2 m 612 +
Cytoplasmic 
and speckled













































n.p. n.r. Inflammatory 
myopathy
D




n.p. n. r. n.p. D




n.p. n. r. n.p. D
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1723 n.r. n.r. n.p. n.p. n.p. n.p. n.r. D
Spiro, 2018 
[34], USA
















56, F A 20 6 days 3258^ >1:20,480# ‑ n.p n.p. n.p. n.p n.p. Pr
table IV. Statin‑associated dermatomyositis (30 case reports). Most Authors used the diagnostic criteria 
according to Bohan and Peter [36,37]
§ ethnicity: African American
* aldolase high: peak = 13.8 IU/l
^ anti‑Mi‑2 positive
# Polish normal values: <1:160
‑ = negative; + = positive; A = atorvastatin; ADM = amyopathic dermatomyositis; ANA = anti‑nuclear 
antibody; anti‑HMGCR = anti ‑3‑hydroxy‑3‑methylglutaryl‑coenzyme A reductase autoantibodies; 
anti‑Jo‑1 = anti‑aminoacyl‑tRNA histidyl synthetase autoantibodies; anti‑Mi‑2 = anti‑chromodomain helicase 
DNA binding proetin 4 Ab; anti‑SRP = anti‑signal recognition particle autoantibodies; CPK = creatine 
phosphokinase; D = definite; EMG = electromyography; F = fluvastatin; HLA‑1 = human leukocyte antigen‑1; 
L = lovastatin; m = months; MRI = magnetic resonance imaging; n.p. = not performed; n.r. = not reported; 
P = pravastatin; Po = possible; Pr = probable; R = rosuvastatin; S = simvastatin; u.k. = unknown; y = years
On the basis of the results shown in Ta‑
bles III and IV, these diseases were more 
frequent in women (66%) and in senile age 
(the median age at the time of diagnosis 
was 68 years). The drugs most frequently 
associated with the disease were atorv‑
astatin and simvastatin in PM and DM, 
respectively.
The exposure period was very variable: in 
the PM there was a minimum of two days, 
in a case concerning an African American 
patients with CPK peak very high [12], 
while the maximum exposure time was of 
25 years in an elderly woman. In DM, the 
exposure duration was shorter (median = 6 
months; range = 6 days‑10 years).
The CPK peak was higher in PM (me‑
dian  =  2802 U/l; range  =  355‑126,000) 
than in DM (median = 1574 U/l; range = 
207‑20,424), but the difference was not sta‑
tistically significant.
In one case of dermatomyositis (55 years, 
F, atorvastatin 80 mg) [34], a normal value 
of CPK was found associated with increased 
aldolase. In three further cases, the CPK was 
lower than 300 U/l.
The determination of ANAs refers only 
to 33 patients: they were positive in 76% 
of patients, i.e. 23 cases (14/18 DM and 
9/15 PM).
Anti‑HMGCR antibodies were dosed in 
a total of 9 patients: those described in the 
> Table continued
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myopathy). It is associated with anti‑3‑hy‑
droxy‑3‑methylglutaryl‑coenzyme A reduc‑
tase antibodies (anti‑HMGCR) [59].
According to some Authors, most patients 
affected by necrotizing myopathy with a his‑
tory of statins, before the discovery of an‑
ti‑HMGCR were classified as polymyositis. 
Statin‑triggered IMNM and polymyositis 
would therefore not be two distinct enti‑
ties, but part of the same pathophysiological 
spectrum also because they respond well to 
immunosuppressive treatment [5,60].
Pathognomonic clinical manifestations 
for dermatomyositis and polymyositis have 
been reported in three adult patients with 
autoimmune necrotizing myopathy positive 
for anti‑HMGCR [61‑63].
In the IMNM, magnetic resonance de‑
tects a characteristic pattern of muscular 
abnormalities involving mainly hip rota‑
tors and glutei: IMNM have significantly 
more widespread muscle edema, atrophy, 
and fatty replacement compared with those 
with polymyositis and dermatomyositis, un‑
like the fascial edema is more common and 
widespread in dermatomyositis [44].
In 2013, a Canadian Working Group 
Consensus defined the main predisposing 
conditions that promote intolerance or side 
effects of statins [64]:
 y Hypothyroidism;
 y Hypovitaminosis D;
 y Low body mass index;
 y Low CoQ10 enzyme level;
 y Excessive use of alcohol;
 y Excessive use of cranberry or grapefruit 
juice;
 y Illicit drugs (amphetamine, cocaine, 
heroin);
 y Drug‑statin interaction;
 y Renal failure;
 y Liver failure;
 y Diabetes mellitus;
 y Biliary obstruction;
 y History of pre‑existing asymptomatic in‑
crease in CPK.
However, a more recent meta‑analysis 
conducted by Nguyen in 2018 found that 
the significant risk factors for myopathy and/
or rhabdomyolysis associated with statins 
were [65]:
 y Age > 65 years;
 y Female gender;
 y Diabetes mellitus;
 y Renal insufficiency;
Brazilian series published in 2018 [12] and 
the recent case published in October 2018 
[34]. All were negative. These antibodies, 
discovered in 2010 [52,53], are currently 
being measured in a few specialized centers. 
Even the anti‑signal recognition particle au‑
toantibodies (anti‑SRPs), mentioned in the 
same series, were negative.
In PM, anti‑Jo antibodies were negative in 
10 out of 14 assays performed. Among the 
4 positive patients, one had antisynthetase 
syndrome. In DM, 12 patients were tested, 
but none was positive.
We found also a case of polymyositis 
during therapy with atorvastatin diag‑
nosed after an episode of rhabdomyolysis 
(CPK  =  14.611 U/l with myoglobinuria) 
from cerivastatin, with subsequent detection 
of positive anti‑Jo‑1 [16].
dISCuSSIon
According to the literature [11,54‑57], 
statins are involved also in other autoim‑
mune diseases, such as interstitial lung 
disease, myasthenia gravis, systemic lupus 
erythematosus, cutaneous lupus, vasculitis, 
autoimmune hepatitis, lichen planus pem‑
phigoides, and pemphigus erythematosus.
Even more cases appeared in recent years 
in literature concerning necrotizing my‑
opathies associated with statins and with 
the coexistence of autoimmune phenom‑
ena [11,55].
From 1992 to November 2018 at least 
58 defined cases of DM (n. 30) and PM (n. 
28), with histological confirmation, associ‑
ated with exposure to statins were described.
It should be noticed that in the analysis 
of the South Australian Myositis database 
including 221 patients with histologically 
confirmed idiopathic inflammatory myosi‑
tis, 68 patients (30.8% of cases) were found 
exposed to statins, at the time of diagnosis: 
27/89 PM, 4/23 DM, 12/24 necrotizing 
myopathy, 20/66 inclusion body myositis, 
and 5/19 nonspecific chronic inflamma‑
tory myositis patients. Exposure to statins 
was found in 30.3% of PM and in 17.4% of 
DM, thereby highlighting an almost 2‑fold 
increased likelihood compared with controls. 
However, details on the type of statin, dos‑
age, or duration of statin exposure was not 
available in this study [58].
Another serious muscle complication as‑
sociated with statin use has recently been 
described: autoimmune necrotizing myopa‑
thy (IMNM: immune‑mediated necrotizing 
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prescribed because it is chemically identical 
to lovastatin.
Berberine does not modify CPK [68], 
while for ezetimibe the incidence of myopa‑
thy/rhabdomyolysis was identical (0.2%) to 
that found in placebo patients. PCSK9 in‑
hibitors may be used in myopathic patients 
at high cardiovascular risk. These fully hu‑
man monoclonal antibodies (e.g. evolucum‑
ab, alirocumab), which act against the pro‑
protein convertase subtilisin/kexyn type 9, 
could be an alternative to statin therapy in 
severe cases of drug toxicity, such as rhab‑
domyolysis [1]. Clinical studies comparing 
statins versus statins + anti‑PCSK9 found no 
differences in muscle and CPK side effects 
between the two groups [69,70]. For patients 
with idiopathic inflammatory myositis and 
with coexistent dyslipidemia, anti‑cholester‑
ol therapy should be implemented, obviously, 
with defined drugs without toxic effects on 
the muscle.
ConCLuSIonS
The present literature review identified 28 
cases of polymyositis and 30 cases of der‑
matomyositis related to exposure to statins.
To my knowledge, this is currently 
the widest research about these two rare 
statin‑triggered pathologies.
Key points
 y Besides the more common side effects on muscle, statins can give rise to autoimmune phenomena
 y Inflammatory myopathies are a very heterogeneous group of illnesses that can present with a very different clinical 
phenotype
 y The main subtypes of myositis should be considered in the differential diagnosis: PM, DM, IMNM, OM/ASS, and IBM
 y The international literature reports 28 cases of polymyositis and 30 cases of dermatomyositis related to exposure to statins
 y It is useful to dose the CPK (and aldolase) before starting statin therapy
 y In case of skin rash or muscular symptoms, antinuclear antibody screening is recommended in patients treated with 
statins
 y Patients who have failed to normalize high CPK (> 10 times the upper range of normal) after statin withdrawal and 
after cortisone therapy should be tested (in addition to ANA and ENA) for myositis‑associated and myositis‑specific 
antibodies (MAAs and MSAs), in particular anti‑SRP and anti‑HMGCR antibodies and, if these are positive, 
undergo muscle biopsy to confirm the diagnosis of inflammatory or autoimmune myopathy
 y Drug therapy is challenging and requires, in addition to corticosteroids, immunosuppressive medications, and intra‑
venous immunoglobulin.
 y New anti‑PCSK9 monoclonal antibodies may be used in high‑risk cardiovascular myopathic patients
 y The choice of anti‑cholesterol therapy in myopathic patients after clinical recovery is yet not defined
 y Cardiovascular disease;
 y Drug‑drug interactions (clarithromycin, 
erythromycin, cyclosporin, mibefradil, 
verapamil, diltiazem, nefazodone, itracon‑
azole, fibrates, gemfibrozil, amiodarone, 
and protease inhibitors);
 y Statin dose;
 y Genetic factors (SLCO1B1 gene muta‑
tion).
It is useful to dose CPK before starting 
statin therapy to discover a subclinical my‑
opathy and to exclude, even if very rare, the 
presence of macro‑creatinekinase [66].
Subsequent CPK checks should be done 
in the third, sixth, and twelfth months be‑
cause most statin myopathies occur within 
the first six months of therapy.
Concerning the case with high aldolase 
[50], it should be pointed out that aldolase 
dosage is useful because its isolated increase 
reflects preferential immune‑mediated dam‑
age affecting early regenerating cells [67].
Regarding the therapy of hypercholes‑
terolemia to be implemented after clini‑
cal recovery in patients with IIMs, to my 
knowledge specific indications do not exist 
in the literature. Drugs with no side effects 
on the muscle should be used. In primary 
prevention, the range of therapy extends 
from nutraceuticals to ezetimibe. As for 
nutraceuticals, monacolin K should not be 
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